Story Content

On Tuesday, India's drug regulator has allowed vaccine developer Serum Institute to enrol kids aged 7-11 years for conducting trial of US drug maker Novavax's Covid-19 vaccine, as the country is preparing to protect children from the novel coronavirus.

Recently, India has administered more than 870 million doses to adults among its population of nearly 1.4 billion.

A subject expert panel of the Central Drugs Standard Control Organization said, "After detailed deliberation, the committee recommended for allowing enrolment of subjects of 7 to 11 years of age group as per the protocol." 

Currently, Serum Institute is conducting a trial of its Covid-19 vaccine Covovax, a domestically produced version of Novavax's shot, in the 12-17 age group and has presented safety data for an initial 100 participants.